SYMDEKO (COPACKAGED) Drug Patent Profile

Which patents cover Symdeko (copackaged), and when can generic versions of Symdeko (copackaged) launch?

Symdeko (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. There are twenty-six patents protecting this drug.

This drug has four hundred and twenty-eight patent family members in forty-one countries.

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Symdeko (copackaged)

Symdeko (copackaged) was eligible for patent challenges on February 12, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 10, 2031. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMDEKO (COPACKAGED)

International Patents:	428
US Patents:	26
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMDEKO (COPACKAGED)

US Patents and Regulatory Information for SYMDEKO (COPACKAGED)

SYMDEKO (COPACKAGED) is protected by thirty-three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent RE50453.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-002	Jun 21, 2019		RX	Yes	No	7,495,103		Y	Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	8,354,427
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	8,410,274		Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	9,012,496
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	10,081,621		Y

International Patents for SYMDEKO (COPACKAGED)

When does loss-of-exclusivity occur for SYMDEKO (COPACKAGED)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMDEKO (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2007235260
Brazil	PI0710965
Canada	2648719
Canada	2869945
China	101460489

Supplementary Protection Certificates for SYMDEKO (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2826776	C20210011 00330	Estonia		PRODUCT NAME: TESAKAFTOOR/IVAKAFTOOR;REG NO/DATE: EU/1/18/1306 06.11.2018
1773816	300748	Netherlands		PRODUCT NAME: IVACAFTOR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120725
1773816	SPC/GB15/041	United Kingdom		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/12/782/001 20120725; UK EU/1/12/782/002 20120725
2826776	202140011	Slovenia		PRODUCT NAME: COMBINATION OF TEZACAFTOR AND IVACAFTOR; NATIONAL AUTHORISATION NUMBER: EU/1/18/1306; DATE OF NATIONAL AUTHORISATION: 20181031; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2826776	21C1018	France		PRODUCT NAME: TEZACAFTOR ET IVACAFTOR, SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/18/1306 20181106

Investment Scenario and Fundamentals Analysis for SYMDEKO (COPACKAGED)

Last updated: February 19, 2026

What Is SYMDEKO and Its Market Position?

SYMDEKO (co-packaged formulation) combines velpatasvir and sofosbuvir, approved by the FDA in 2017 for treating chronic hepatitis C virus (HCV) infection across all genotypes (1-6). It is marketed by Gilead Sciences. As a direct-acting antiviral (DAA), SYMDEKO addresses a significant global health burden, with estimated market size reaching $20 billion by 2028 (Persistence Market Research, 2022).

What Is the Current Revenue and Market Penetration?

Gilead reports SYMDEKO sales of approximately $2.2 billion in 2022, with steady growth due to expanding access, especially in emerging markets. The drug's patent protection extends until 2028, with some markets facing generic competition thereafter. Key regional sales include:

Region	2022 Revenue (USD millions)	Market Share	Key Dynamics
U.S.	1,200	55%	High coverage, brand dominance
Europe	500	23%	Competitive but growing access
Rest of World	500	22%	Expanding access, pipeline influence

Gilead's strategic focus on hepatitis C markets positions SYMDEKO as a leading product, though increased competition from generics may pressure prices beyond 2028.

What Are the Key Drivers and Risks?

Drivers:

1. Global HCV prevalence: Estimated at 71 million globally (WHO, 2021). High unmet need in low- and middle-income countries boosts demand.
2. Access initiatives: Gilead's negotiations with governments and payers expand treatment programs.
3. Pricing and reimbursement: Tiered pricing strategies improve affordability in emerging markets.
4. Pipeline developments: Gilead's pipeline aims to replace or supplement SYMDEKO with newer DAAs.

Risks:

1. Patent expiration: Patents expiring in 2028 risk generic erosion, with potential revenue halving.
2. Generic competition: Several biosimilars and generics approved or under development in key markets post-2028.
3. Pricing pressures: Governments and payers push for lower prices, impacting margins.
4. Regulatory and approval delays: Some markets face slow registration processes.

How Does Gilead’s Financial Position Support SYMDEKO’s Prospects?

Gilead's 2022 financials reveal:

Metric	2022 Data	Change (YoY)	Comments
Revenue	$27.3 billion	+3%	Overall growth driven by HIV and oncology
R&D Expenses	$3 billion	+15%	Focused on hepatitis and other infectious diseases
Operating Margin	32%	-2%	Reflects increased R&D investment

Gilead's cash reserves of $22 billion (2022) provide capacity for pipeline investments and strategic licensing.

What Is the Investment Outlook?

Short-Term (Next 2-3 years):

• Revenues expected to remain stable, boosted by access programs and market expansion.
• Patent exclusivity preserves high margins.
• Market growth driven by new treatment guidelines broadening indications.

Long-Term (2028 and beyond):

• Revenue decline anticipated due to patent expiry.
• Generic competition forecast to reduce sales by 50% or more.
• Potential for partnerships or licensing to sustain revenues.

Valuation Considerations:

• Current P/E ratio approximately 14x (based on 2022 earnings), aligning with biotech industry averages.
• Sales multiple for niche drugs: typically 8-12x, with potential upgrades if pipeline progresses.

How Do Competitors Compare?

Company	Key Product	2022 Revenue	Patent Status	Notes
AbbVie	MAVYRET, VONSA	$1.5B	2027	Competitive pricing, expanding access
Merck	Zepatier	$300M	2025	Market share declining due to newer DAAs
Bausch Health	Zepatier	$200M	2025	Smaller player, less impact

Gilead’s early market leadership positions it favorably, but future growth depends on patent protections and pipeline success.

What Are the Strategic Moves Recommended for Investors?

• Monitor patent expiry timelines and pipeline developments.
• Evaluate access expansion in emerging markets.
• Track pricing trends and payer negotiations.
• Assess competition from generics and biosimilars post-2028.
• Consider diversified hepatitis C portfolios to mitigate patent expiration effects.

---

Key Takeaways

• SYMDEKO is a core product for Gilead with stable revenues and high market penetration.
• Revenue growth is driven by global access efforts, but patent expiry in 2028 will significantly impact sales.
• Gilead's financial strength supports ongoing R&D and licensing.
• Competitive landscape shows stable but eroding margins due to impending generic entries.
• Investment potential hinges on pipeline success, patent protection, and market expansion.

---

Frequently Asked Questions

Q1: When does SYMDEKO's patent protection expire in major markets?
A1: Patent protection expires around 2028 in the U.S. and Europe, with some extensions possible through supplementary protections or patent filings.

Q2: What are the main competitors to SYMDEKO?
A2: Main competitors include AbbVie's MAVYRET, Merck’s Zepatier, and generic formulations entering markets post-patent expiration.

Q3: How significant is generic competition for SYMDEKO?
A3: After 2028, generic competition is expected to significantly reduce sales, potentially halving revenues due to lower-priced biosimilars and generics.

Q4: Are there ongoing pipeline developments that could replace SYMDEKO?
A4: Gilead is progressing several next-generation DAAs, but none currently hold the global market dominance of SYMDEKO. Success in licensing and approvals is critical.

Q5: What factors influence SYMDEKO’s long-term profitability?
A5: Patent protection, access expansion, pricing strategies, pipeline innovation, and competitive dynamics all influence long-term prospects.

---

References

[1] Persistence Market Research. (2022). Hepatitis C Virus (HCV) Treatment Market Outlook. Retrieved from https://www.persistencemarketresearch.com

[2] World Health Organization. (2021). Hepatitis C fact sheet. Retrieved from https://www.who.int

[3] Gilead Sciences. (2023). Fiscal Year 2022 Annual Report.